212
Participants
Start Date
April 24, 2020
Primary Completion Date
April 9, 2021
Study Completion Date
June 24, 2021
Sirukumab
Participants will receive single dose infusion of sirukumab on Day 1.
Placebo
Participants will receive placebo IV single dose infusion on Day 1.
Standard of Care (SOC)
SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
SUNY Upstate Medical University, Syracuse
East Carolina University, Greenville
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale
Beaumont Health Systems, Royal Oak
Henry Ford Hospital, Detroit
Mercury Street Medical Group, PLLC, Butte
Loyola University Medical Center, Maywood
Great Lakes Clinical Trials, Chicago
University of Illinois College of Medicine at Peoria, Peoria
Washington University School of Medicine, St Louis
Louisiana State University Health Sciences Center, New Orleans
Baylor Scott & White Research Institute, Dallas
Baylor All Saints Medical Center at Fort Worth, Fort Worth
MemorialCare Research Miller Children's and Women's Hospital Long Beach, Long Beach
Hoag Memorial Hospital, Newport Beach
Saint Michaels Medical Center - Infectious Disease, Newark
Janssen Pharmaceutica N.V., Belgium
INDUSTRY